Evotec Faces Analyst Target Cut Amid Restructuring Phase

Berenberg lowers Evotec's price target to €9.70, citing near-term costs of its 'Horizon' overhaul, but maintains a Buy rating on long-term potential. Shares recently traded at €4.26.

Analysts at Berenberg Bank have revised their valuation for Evotec SE, lowering their price target for the Hamburg-based drug discovery specialist while maintaining a positive long-term stance. The adjustment comes as the company navigates a significant corporate overhaul, known as the "Horizon" program, which is expected to weigh on near-term financial performance.

Maintaining a "Buy" Despite Near-Term Headwinds

In a recent research note, Berenberg strategists reaffirmed their "Buy" recommendation on Evotec shares. However, they set a new price target of €9.70, down from their previous assessment. This revision primarily reflects the anticipated short-term costs and operational complexity associated with the ongoing restructuring initiative. The "Horizon" program is designed to optimize the company's cost structure and secure long-term profitability, but its implementation phase is currently creating margin pressure.

The bank's analysts continue to see substantial upside potential for the stock. This outlook is highlighted by the significant gap between the new target and the recent trading price. Evotec shares concluded Friday's session at €4.26, following a decline of approximately 27% over the past month.

Market and Internal Challenges Converge

Evotec's path forward is shaped by both its internal transformation and a demanding external market environment. Industry-wide factors, such as political pressure on drug pricing stemming from U.S. negotiations, are affecting sentiment across the biopharma value chain. Consequently, investors are keenly awaiting concrete updates to gauge the true progress of Evotec's strategic shift.

Management has scheduled two key events that will serve as critical checkpoints for the restructuring's validity:
* April 8, 2026: Publication of the Group's Annual Report
* May 6, 2026: Release of the Q1 interim statement

These disclosures will be scrutinized for evidence of how effectively the "Horizon" measures are taking hold. A primary focus will be the company's financial guidance for the remainder of 2026, which should indicate whether existing pharmaceutical partnerships can offset the margin erosion occurring during this transitional period.